Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology
Cougar Biotechnology Announces Allowance of IND for CB3304 (Noscapine)
August 5th, 2007
Cougar Biotechnology, Inc. (OTCBB:CGRB) announced that its Investigational New Drug (IND) application for the Company's drug CB3304 (noscapine) has been allowed by the U.S. Food and Drug Administration (FDA). This will allow Cougar to conduct a Phase I clinical trial of CB3304, an orally active inhibitor of microtubule dynamics, for the treatment of relapsed or refractory multiple myeloma in the United States. Cougar expects to conduct the Phase I clinical trial at a number of clinical sites, including Weill Cornell Medical College and Columbia Presbyterian Medical Center. Dr. Arie Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology,...
Source: Medical Letter on the CDC & FDA (2007-08-05)
|
